News
Rinvoq is MHLW approved in Japan to treat non-radiographic axial spondyloarthritis
Rinvoq, a JAK inhibitor, from AbbVie expanded its label in Japan to include non-radiographic axial spondyloarthritis (nr-axSpA) inadequately controlled with existing therapies
Aside from the new indication, it is already approved for rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ankylosing spondylitis, and ulcerative colitis (all in cases inadequately controlled with existing therapies).
Condition: Axial Spondyloarthritis
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins